Chronic systemic immune activation is the strongest predictor of progression to AIDS in untreated HIV infection and persists at abnormal levels in people on suppressive antiretroviral therapy, where it is linked to non-AIDS morbidity and mortality. A landmark 2006 study proposed that translocation of microbial products across a damaged gastrointestinal barrier is a cause of this activation, but rested on cross-sectional correlations. The unresolved problem, unified by one objective, is to establish the causal and mechanistic contribution of microbial translocation to chronic immune activation: why natural, nonpathogenic SIV hosts avoid it, which microbial products beyond lipopolysaccharide drive innate activation, how host genetics modulate responsiveness, and whether interrupting translocation or its downstream sensing reduces immune activation and alters disease course.

Background

HIV infection causes progressive loss of CD4+ T cells, the main target cells of the virus, and untreated infection leads to AIDS. Beyond viral load itself, the strongest predictor of disease progression is chronic systemic immune activation — a state in which T cells, monocytes, and other immune cells display markers of activation and inflammation even in the absence of obvious opportunistic infection. The gastrointestinal (GI) tract harbors most of the body's lymphocytes and an enormous microbial community, separated from it by a single-layer epithelial barrier. During acute HIV and pathogenic simian immunodeficiency virus (SIV) infection of macaques, the GI mucosa suffers massive CD4+ T-cell depletion and epithelial damage, and it was proposed that microbial products then cross the compromised barrier into the circulation ('microbial translocation'). Lipopolysaccharide (LPS, endotoxin), a component of Gram-negative bacterial outer membranes, was used as a circulating marker of this process; the limulus amebocyte lysate (LAL) assay detects its bioactivity in plasma. Related measurable markers include soluble CD14 (sCD14, shed when monocytes respond to LPS) and endotoxin core antibodies (EndoCAb). Antiretroviral therapy — earlier called HAART, now ART — suppresses viral replication but does not fully normalize immune activation. Nonhuman primates such as sooty mangabeys and African green monkeys are 'natural hosts' of SIV: they sustain high lifelong viral replication without progressing to AIDS, despite marked mucosal CD4 depletion in mangabeys, and apparently without sustained microbial translocation. Th17 cells are interleukin-17-producing CD4+ T helper cells that maintain mucosal antimicrobial defense and epithelial integrity; plasmacytoid dendritic cells (pDC) are the principal producers of type I interferon (IFN-α) and sense viral and microbial nucleic acids through endosomal Toll-like receptors (TLR7 and TLR9). In the source study (Brenchley et al., Nature Medicine, 2006), plasma LPS was significantly elevated in chronically HIV-infected individuals and in SIV-infected rhesus macaques, was bioactive in vivo, correlated with sCD14, EndoCAb depletion, and markers of innate and adaptive T-cell activation, was only partially reduced by effective antiretroviral therapy, and was not elevated in nonpathogenic SIV infection of sooty mangabeys. The authors stated that these data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection, and later measurement work showed that the LAL assay is partially masked by plasma constituents, complicating quantitative interpretation of LPS levels.

Problem Statement

Determine the causal role and mechanisms of microbial translocation in HIV-associated chronic systemic immune activation, the open question left by the source study, decomposed as follows: (1) define the cellular and molecular mechanisms by which natural, nonpathogenic SIV hosts (such as sooty mangabeys and African green monkeys) preserve mucosal barrier integrity and avoid sustained microbial translocation despite mucosal CD4+ T-cell depletion; (2) establish the causal and temporal relationships among HIV replication, translocation of microbial products, systemic immune activation, and CD4+ T-cell reconstitution on antiretroviral therapy, including why endotoxemia and markers such as sCD14 and EndoCAb incompletely normalize despite viral suppression; (3) delineate the contribution of translocated products other than LPS (such as flagellin and microbial nucleic acids sensed through Toll-like receptor pathways) to innate responses, including plasmacytoid dendritic cell and IFN-α responses; (4) identify host factors, including innate-sensor polymorphisms, that modulate responsiveness to translocated products and distinguish progression from nonprogression; and (5) determine by rigorous interventional studies whether preventing microbial translocation, restoring mucosal epithelial and immunological integrity, or blocking downstream sensing and signaling pathways reduces chronic immune activation and alters disease course. These components jointly serve the single objective of establishing whether, how, and to what extent microbial translocation causally drives chronic immune activation in HIV infection, with completed trial results not producible within a written solution.

References

  1. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine 12(12):1365-1371 (2006). DOI: 10.1038/nm1511. https://doi.org/10.1038/nm1511
  2. Gordon SN, Klatt NR, Bosinger SE, Brenchley JM, Milush JM, Engram JC, Dunham RM, Paiardini M, Klucking S, Danesh A, Strobert EA, Apetrei C, Pandrea IV, Kelvin D, Douek DC, Staprans SI, Sodora DL, Silvestri G. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. Journal of Immunology 179(5):3026-3034 (2007). DOI: 10.4049/jimmunol.179.5.3026. https://doi.org/10.4049/jimmunol.179.5.3026
  3. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, Scheinberg P, Price DA, Hage CA, Kholi LM, Khoruts A, Frank I, Else J, Schacker T, Silvestri G, Douek DC. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112(7):2826-2835 (2008). DOI: 10.1182/blood-2008-05-159301. https://doi.org/10.1182/blood-2008-05-159301
  4. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, Barrat FJ, Coffman RL, Staprans SI, Feinberg MB. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nature Medicine 14(10):1077-1087 (2008). DOI: 10.1038/nm.1871. https://doi.org/10.1038/nm.1871
  5. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, Mold J, Swainson L, Barbour JD, Baskin CR, Palermo R, Pandrea I, Miller CJ, Katze MG, McCune JM. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathogens 5(2):e1000295 (2009). DOI: 10.1371/journal.ppat.1000295. https://doi.org/10.1371/journal.ppat.1000295
  6. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, Asher AI, Deeks SG, Douek DC, Brenchley JM. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. Journal of Infectious Diseases 199(8):1177-1185 (2009). DOI: 10.1086/597476. https://doi.org/10.1086/597476
  7. Marchetti G, Bellistrì GM, Borghi E, Tincati C, Ferramosca S, La Francesca M, Morace G, Gori A, Monforte AD. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 22(15):2035-2038 (2008). DOI: 10.1097/QAD.0b013e3283112d29. https://doi.org/10.1097/QAD.0b013e3283112d29
  8. Cassol E, Malfeld S, Mahasha P, van der Merwe S, Cassol S, Seebregts C, Alfano M, Poli G, Rossouw T. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. Journal of Infectious Diseases 202(5):723-733 (2010). DOI: 10.1086/655229. https://doi.org/10.1086/655229
  9. Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, Sleasman JW, Goodenow MM. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 24(9):1281-1290 (2010). DOI: 10.1097/QAD.0b013e328339e228. https://doi.org/10.1097/QAD.0b013e328339e228
  10. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. Journal of Infectious Diseases 201(12):1788-1795 (2010). DOI: 10.1086/652749. https://doi.org/10.1086/652749
  11. Oh DY, Baumann K, Hamouda O, Eckert JK, Neumann K, Kücherer C, Bartmeyer B, Poggensee G, Oh N, Pruss A, Jessen H, Schumann RR. A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS 23(3):297-307 (2009). DOI: 10.1097/QAD.0b013e32831fb540. https://doi.org/10.1097/QAD.0b013e32831fb540
  12. Byakwaga H, Kelly M, Purcell DF, French MA, Amin J, Lewin SR, Haskelberg H, Kelleher AD, Garsia R, Boyd MA, Cooper DA, Emery S, CORAL Study Group. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. Journal of Infectious Diseases 204(10):1532-1540 (2011). DOI: 10.1093/infdis/jir559. https://doi.org/10.1093/infdis/jir559
  13. Balagopal A, Gama L, Franco V, Russell JN, Quinn J, Higgins Y, Smeaton LM, Clements JE, Thomas DL, Gupta A, NWCS 319 and ACTG 5175 study team. Detection of microbial translocation in HIV and SIV infection using the Limulus amebocyte lysate assay is masked by serum and plasma. PLoS ONE 7(8):e41258 (2012). DOI: 10.1371/journal.pone.0041258. https://doi.org/10.1371/journal.pone.0041258
  14. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nature Reviews Microbiology 10(9):655-666 (2012). DOI: 10.1038/nrmicro2848. https://doi.org/10.1038/nrmicro2848
  15. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends in Microbiology 21(1):6-13 (2013). DOI: 10.1016/j.tim.2012.09.001. https://doi.org/10.1016/j.tim.2012.09.001
  16. Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL, Douek DC, Tressler R, Read SW, Wilson CC, Deeks SG, Lederman MM, Gandhi RT, AIDS Clinical Trials Group A5296 Team. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. Journal of Infectious Diseases 210(10):1549-1554 (2014). DOI: 10.1093/infdis/jiu305. https://doi.org/10.1093/infdis/jiu305
  17. Tenorio AR, Chan ES, Bosch RJ, Macatangay BJ, Read SW, Yesmin S, Taiwo B, Margolis DM, Jacobson JM, Landay AL, Wilson CC, A5286 Team. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. Journal of Infectious Diseases 211(5):780-790 (2015). DOI: 10.1093/infdis/jiu515. https://doi.org/10.1093/infdis/jiu515
  18. Villar-García J, Hernández JJ, Güerri-Fernández R, González A, Lerma E, Guelar A, Saenz D, Sorlí L, Montero M, Horcajada JP, Knobel Freud H. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial. Journal of Acquired Immune Deficiency Syndromes 68(3):256-263 (2015). DOI: 10.1097/QAI.0000000000000468. https://doi.org/10.1097/QAI.0000000000000468
  19. Svärd J, Paquin-Proulx D, Buggert M, Noyan K, Barqasho B, Sönnerborg A, Nowak P. Role of translocated bacterial flagellin in monocyte activation among individuals with chronic HIV-1 infection. Clinical Immunology 161(2):180-189 (2015). DOI: 10.1016/j.clim.2015.08.018. https://doi.org/10.1016/j.clim.2015.08.018
  20. d'Ettorre G, Ceccarelli G, Giustini N, Serafino S, Calantone N, De Girolamo G, Bianchi L, Bellelli V, Ascoli-Bartoli T, Marcellini S, Turriziani O, Brenchley JM, Vullo V. Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the "Probio-HIV" Clinical Trial. PLoS ONE 10(9):e0137200 (2015). DOI: 10.1371/journal.pone.0137200. https://doi.org/10.1371/journal.pone.0137200
  21. Hao XP, Lucero CM, Turkbey B, Bernardo ML, Morcock DR, Deleage C, Trubey CM, Smedley J, Klatt NR, Giavedoni LD, Kristoff J, Xu A, Del Prete GQ, Keele BF, Rao SS, Alvord WG, Choyke PL, Lifson JD, Brenchley JM, Apetrei C, Pandrea I, Estes JD. Experimental colitis in SIV-uninfected rhesus macaques recapitulates important features of pathogenic SIV infection. Nature Communications 6:8020 (2015). DOI: 10.1038/ncomms9020. https://doi.org/10.1038/ncomms9020
  22. Ortiz AM, Brenchley JM. Microbial translocation: translating simian immunodeficiency virus to HIV. Current Opinion in HIV and AIDS 13(1):15-21 (2018). DOI: 10.1097/COH.0000000000000424. https://doi.org/10.1097/COH.0000000000000424
  23. Raehtz KD, Barrenäs F, Xu C, Busman-Sahay K, Valentine A, Law L, Ma D, Policicchio BB, Wijewardana V, Brocca-Cofano E, Trichel A, Gale M, Keele BF, Estes JD, Apetrei C, Pandrea I. African green monkeys avoid SIV disease progression by preventing intestinal dysfunction and maintaining mucosal barrier integrity. PLoS Pathogens 16(3):e1008333 (2020). DOI: 10.1371/journal.ppat.1008333. https://doi.org/10.1371/journal.ppat.1008333
  24. Mehraj V, Ramendra R, Isnard S, Dupuy FP, Ponte R, Chen J, Kema I, Jenabian MA, Costinuik CT, Lebouché B, Thomas R, Coté P, Leblanc R, Baril JG, Durand M, Chartrand-Lefebvre C, Tremblay C, Ancuta P, Bernard NF, Sheppard DC, Routy JP, Montreal Primary HIV Infection Study and Canadian HIV and Aging Cohort Study Groups. Circulating (1→3)-β-D-glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 70(2):232-241 (2020). DOI: 10.1093/cid/ciz212. https://doi.org/10.1093/cid/ciz212
  25. Ouyang J, Yan J, Zhou X, Isnard S, Harypursat V, Cui H, Routy JP, Chen Y. Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV. Frontiers in Immunology 14:1173956 (2023). DOI: 10.3389/fimmu.2023.1173956. https://doi.org/10.3389/fimmu.2023.1173956
  26. Ruderman SA, Hunt PW, Beck-Engeser G, Ambayec G, Willig AL, Saag MS, Napravnik S, Cachay E, Bamford L, Landay A, Drumright LN, Mixson LS, Whitney BM, Nance RM, Kitahata MM, Crane HM, Delaney JAC, Hahn AW. Biomarkers of microbial translocation and generalized inflammation are associated with frailty among people with HIV. AIDS 39(2):153-161 (2025). DOI: 10.1097/QAD.0000000000004047. https://doi.org/10.1097/QAD.0000000000004047